New early breast cancer option recommended by NICE
The drug is recommended provided that Herceptin (trastuzumab) is the only HER2-directed adjuvant treatment people have had.
Read More
Tag: neoadjuvant
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
